NCT06307938 Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer
| NCT ID | NCT06307938 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Helse Nord-Trøndelag HF |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2025-03-10 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2025-03-10 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CoLiQ is a clinical study designed to evaluate the clinical usefulness of circulating tumor DNA (ctDNA) markers found in blood, as a liquid biopsy for diagnosis, prognosis and follow-up of colorectal cancer. The main questions it aims to answer are: 1) Can a panel of ctDNA markers identify CRC patients among the other patients summoned for colonoscopy? and 2) Does the type, number and level of ctDNA markers vary with the subtype and clinical course of CRC? Participants will be asked to answer a questionnaire and give a blood sample at inclusion. In addition, patients with CRC will be asked to give an extra test tube at their routine treatment and follow-up blood sampling.
Eligibility Criteria
Inclusion Criteria: * Patient ≥ 18 years old summoned for colonoscopy * Patient able to understand and sign written informed consent Exclusion Criteria: * Patient \< 18 years old * Patient unable to understand or give written informed consent * Patient unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the investigator as unlikely to complete the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06307938 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06307938 currently recruiting?
Yes, NCT06307938 is actively recruiting participants. Contact the research team at eivor.a.laugsand@ntnu.no for enrollment information.
Where is the NCT06307938 trial being conducted?
This trial is being conducted at Levanger, Norway.
Who is sponsoring the NCT06307938 clinical trial?
NCT06307938 is sponsored by Helse Nord-Trøndelag HF. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.